Metabolic Abnormalities and Reprogramming in Cats with Naturally Occurring Hypertrophic Cardiomyopathy
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15135 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Qinghong Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nestlé Purina Research, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Cat Diseases, Metabolome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nestlé Purina PetCare Company.
Abstract (Originalsprache)
Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress. Hypertrophic cardiomyopathy (HCM) is a common heart condition, affecting approximately 15% of the general cat population. Feline HCM shares phenotypical and genotypical similarities with human HCM, but the disease mechanisms for both species are incompletely understood. Our goal was to characterize global changes in metabolome between healthy control cats and cats with different stages of HCM.
Methods
Serum samples from 83 cats, the majority (70/83) of which were domestic shorthair and included 23 healthy control cats, 31 and 12 preclinical cats with American College of Veterinary Internal Medicine (ACVIM) stages B1 and B2, respectively, and 17 cats with history of clinical heart failure or arterial thromboembolism (ACVIM stage C), were collected for untargeted metabolomic analysis. Multiple linear regression adjusted for age, sex and body weight was applied to compare between control and across HCM groups.
Results
Our study identified 1253 metabolites, of which 983 metabolites had known identities. Statistical analysis identified 167 metabolites that were significantly different among groups (adjusted P < 0.1). About half of the differentially identified metabolites were lipids, including glycerophospholipids, sphingolipids and cholesterol. Serum concentrations of free fatty acids, 3-hydroxy fatty acids and acylcarnitines were increased in HCM groups compared with control group. The levels of creatine phosphate and multiple Krebs cycle intermediates, including succinate, aconitate and α-ketoglutarate, also accumulated in the circulation of HCM cats. In addition, serum levels of nicotinamide and tryptophan, precursors for de novo NAD+ biosynthesis, were reduced in HCM groups versus control group. Glutathione metabolism was altered. Serum levels of cystine, the oxidized form of cysteine and cysteine-glutathione disulfide, were elevated in the HCM groups, indicative of heightened oxidative stress. Further, the level of ophthalmate, an endogenous glutathione analog and competitive inhibitor, was increased by more than twofold in HCM groups versus control group. Finally, several uremic toxins, including guanidino compounds and protein bound putrescine, accumulated in the circulation of HCM cats.
Conclusions
Our study provided evidence of deranged energy metabolism, altered glutathione homeostasis and impaired renal uremic toxin excretion. Altered lipid metabolism suggested perturbed structure and function of cardiac sarcolemma membrane and lipid signalling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nestlé Purina Research, St. Louis, Missouri, USA.
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Animal Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
- Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Qinghong Li, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström
Förderung
- Nestlé Purina PetCare Company
Zitieren
APA
Li, Q., Homilius, M., Achilles, E., Massey, L. K., Convey, V., Ohlsson, Å., Ljungvall, I., Häggström, J., Boler, B. V., Steiner, P., Day, S., MacRae, C. A., & Oyama, M. A. (2025). Metabolic Abnormalities and Reprogramming in Cats with Naturally Occurring Hypertrophic Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.15135
Vancouver
Li Q, Homilius M, Achilles E, Massey LK, Convey V, Ohlsson Å, et al. Metabolic Abnormalities and Reprogramming in Cats with Naturally Occurring Hypertrophic Cardiomyopathy. ESC Heart Failure. 2025. doi:10.1002/ehf2.15135
BibTeX
@article{Li2025,
author = {Li, Qinghong and Homilius, Max and Achilles, Erin and Massey, Laura K and Convey, Victoria and Ohlsson, Åsa and Ljungvall, Ingrid and Häggström, Jens and Boler, Brittany Vester and Steiner, Pascal and Day, Sharlene and MacRae, Calum A and Oyama, Mark A},
title = {Metabolic Abnormalities and Reprogramming in Cats with Naturally Occurring Hypertrophic Cardiomyopathy},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15135}
}
EUVIMED